Carlo Bastianelli

ORCID: 0000-0003-3141-4022 · 7 papers in corpus
review 2019
Therapeutics and clinical risk management ·doi:10.2147/tcrm.s147318

Uterine fibroids are the most common gynecological disorder, classically requiring surgery when symptomatic. Although attempts at finding a nonsurgical cure date back to centuries, it is only around the middle of the last century that serio…

review 2017
·doi:10.1080/17512433.2017.1356718

Introduction: The pharmacodynamic effects of various combined oral estrogen-progestin combinations (COC) are examined for their components alone or in the various combined formulations. Special emphasis is given to products containing natur…

nonrandomized-trial 2014
BioMed research international ·doi:10.1155/2014/815127

OBJECTIVE: Evaluate if different bleeding patterns associated with the use of the levonorgestrel intrauterine system (LNG-IUS) are associated with different uterine and endometrial vascularization patterns, as evidenced by ultrasound power …

review 2014
Expert opinion on pharmacotherapy ·doi:10.1517/14656566.2014.914494

INTRODUCTION: Several selective progesterone receptor modulators (SPRMs) show promise in several areas of medicine and this work has been summarized by us in 2008. AREAS COVERED: Since the publication of our reviews, several developments h…

nonrandomized-trial 2011
Contraception ·doi:10.1016/j.contraception.2011.01.020

BACKGROUND: The levonorgestrel-releasing intrauterine system (LNG-IUS) was first marketed in 1990 in Finland. Since then, it has been approved in approximately 120 countries throughout the world, with almost 50 million women-years of cumula…

review 2008
Drugs of today (Barcelona, Spain : 1998) ·doi:10.1358/dot.2008.44.12.1299292

The original form of hormonal contraception ("the Pill") has developed into a variety of modalities administered through different routes: oral, intramuscular, subcutaneous, transdermal, intrauterine or intravaginal, and intranasal (abandon…

review 2008
Expert opinion on pharmacotherapy ·doi:10.1517/14656566.9.14.2473

BACKGROUND: Synthetic compounds can bind to progesterone receptors and these progesterone receptor ligands exhibit a spectrum of activities ranging from pure antagonism to a mixture of agonism and antagonism. These substances have been clas…